ReviewCancers2025
Recent Advances in Ablative Therapies for Hepatocellular Carcinoma.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Advances in liver transplantation for hepatic malignancies.Hepatic oncology · 2026Review
- Review
- Comparative efficacy of liver resectionTranslational cancer research · 2026Article
- Optical-thermal modeling and treatment planning of ICG-enhanced interstitial photothermal therapy using cylindrical diffuser fibers.Lasers in medical science · 2026Article
- Baseline Hemoglobin Predicts Oncologic Outcomes in Intrahepatic Cholangiocarcinoma Treated With Yttrium-90 Radioembolisation: A Retrospective Cohort Study of 136 Patients.Journal of medical imaging and radiation oncology · 2026Article
- A bibliometric analysis of research trends and hotspots on recurrence after thermal ablation for hepatocellular carcinoma 2005-2025.Discover oncology · 2026Article
- Interventional Radiology in the Management of Parathyroid Disorders: Current Diagnostic and Therapeutic Approaches.Journal of clinical medicine · 2026Review
- Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation.Hepatology international · 2026Article
- Yttrium-90 Transarterial Radioembolization for Intrahepatic Cholangiocarcinoma: A Comprehensive Review.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with curative surgical interventions feasible for a minority of patients. This review highlights recent advances in thermal (e.g., radiofrequency ablation, microwave ablation, and cryoablation) and nonthermal (e.g., ethanol ablation and irreversible electroporation) ablative modalities as curative-intent alternatives to surgery. Evolving applications of transcatheter intra-arterial radioembolization (TARE) with ablative dosimetry will be explored, and histotripsy, an emerging technology, will be introduced.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.